Global Sleep Apnea Devices Market is Expected to Reach USD 10.6 Billion by 2025 : Fior Markets
/
Date22 Feb 2020
Email Print Friendly Share Newark, NJ, Feb. 21, 2020 (GLOBE NEWSWIRE) — As per the report published by Fior Markets, the global sleep apnea devices market... Read More →
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
/
Date22 Feb 2020
Email Print Friendly Share PALO ALTO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq:... Read More →
Capital Power declares dividends for its Common and Preference shares
/
Date22 Feb 2020
Email Print Friendly Share EDMONTON, Alberta, Feb. 21, 2020 (GLOBE NEWSWIRE) — The Board of Directors for Capital Power Corporation (TSX: CPX) (Capital Power) declared... Read More →
EURO Ressources – Communiqué information réglementée – Mise à disposition du rapport financier annuel 2019
/
Date22 Feb 2020
Email Print Friendly Share COMMUNIQUÉ Paris: EUR EURO RESSOURCES S.A. COMMUNIQUE INFORMATION REGLEMENTEE MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2019 PARIS, France,... Read More →
MegumaGold to Acquire Palladium Project in British Columbia
/
Date22 Feb 2020
Email Print Friendly Share Figure 1 PD Claims HALIFAX, Nova Scotia, Feb. 21, 2020 (GLOBE NEWSWIRE) — MegumaGold Corp. (CSE: NSAU, OTC: NSAUF, FWB: 2CM2)... Read More →
Atlantica to Present Fiscal Year 2019 Financial Results on February 27
/
Date22 Feb 2020
Email Print Friendly Share Atlantica to Present Fiscal Year 2019 Financial Results on February 27 February 21, 2020 – Atlantica Yield (NASDAQ: AY), the sustainable... Read More →
The Board of Directors approved the financial statements as at 31 December 2018. NAV of Euro 5.5 million. Ebitda of Euro -0.5 million. Net result equal to Euro -14.4 million
/
Date22 Feb 2020
Email Print Friendly Share PRESS RELEASE 21 FEBRUARY 2020 The Board of Directors approved the financial statements as at 31 December 2018. NAV of Euro 5.5... Read More →
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
/
Date22 Feb 2020
Email Print Friendly Share – First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –– NEXLETOL Lowers LDL-Cholesterol... Read More →